with pancreatic tumour cells, whereas 50% and 18% of the activity remained after absorption with normal pancreas homogenate and a mixed non-pancreatic tumourcell pool, respectively. Immunofluorescent staining of pancreatic tumour sections indicated that the antibody was localized on the membrane of ductular epithelial cells. Challenge of immunocompetent mice using this procedure has produced a polyspecific antiserum with signs of selectivity for the circulating antigens released from pancreatic cancer cells, and may provide a route to the production of antibody against specific tumour components.
CANCER CELLS may evade immunological recognition by shedding their surface antigens (Alexander, 1974; Baldwin et al., 1974) . These antigens are glycoproteins or whole plasma membrane fragments (De Broe et al., 1977) which circulate in a free state or complex with host immunoglobulins (Sjogren et al., 1971; Bowen et al., 1975) . Although a number of groups have demonstrated the release of human and animal cell-surface proteins into the serum of tumour-bearing animals (Jamasbi et al., 1978; Nordquist et al., 1978;  Rao & Bonavida, 1977; Primus et al., 1976 ) a study of this process is complicated by the host's immune system.
The availability of human tumour xenografts grown in nude mice provides a model in which human proteins are released into the blood stream of an immunedeficient animal. The aim of this study was to ascertain whether an antibody response against these circulating human tumour antigens could be achieved by injection of serum from tumour-bearing animals into immunocompetent hairy litter-mates. Using this immunization regime it should be possible to produce a polyspecific antiserum recognising both tumour and normal components that are shed from the cell surface. The possibility of selecting antibodies to specific circulating tumour components by eventually fusing the spleen cells of these animals with a myeloma to produce monoclonal antibodies should be applicable to all solid tumours, and may have considerable clinical application.
MATERIALS AND METHODS
Animals.-Four-6-w eek-old female congenitally athymic (nu/nu) mice and their hairy litter-mates wrere bred at the Imperial Cancer Research Fund (ICRF) Laboratories. Nude mice were bred and maintained in sterile conditions in a negative-pressure isolator. Hairy litter mates (nu/ +) were maintained in conventional conditions. Cell lines.-Human pancreatic exocrine adenocarcinoma cells (GER) and a normal human fibroblast cell line derived from the same tumour tissue (GF) were cultured and harvested as previously described . Human foetal pancreatic fibroblasts (FB) derived from a 9-week-old embryo (Tissue Bank, Royal Marsden Hospital, London) and a fibroblast cell line from a second pancreatic tumour (HF) were established in a similar way.
Lymphoblastoid and myeloid cell lines HSB2 (Adams et al., 1968) and HL60 (Collins et al., 1979) , and a breast carcinoma line MDA-157 (Young et al., 1974) . A murine tumour (MP) was induced in nude mice with polyoma virus. To establish cell lines from the xenografts, tissue was minced with crossed scalpels and dispersed into 25cm2 flasks with 3 ml of medium. Tumour cells formed colonies of epithelial cells, which were passaged after 3-4 weeks. Human or murine tumour origin was confirmed by chromosome analysis (Schwartzacher & Wolf, 1974) .
Immunization of hairy litter-mates with serum from tumour-bearing nude mice.-Serum was collected by cardiac puncture from 20 tumour-bearing nude mice when the tumours measured 1-25 cm2. Mice in 4 groups (GER-A, B, D; WB) of 6 hairy litter-mates received 0-4 ml of serum, emulsified in complete Freund's adjuvant (1:1 v/v), -which was divided between 4 sites and given s.e. on Day 0. Two similar injections were given at 14 and 28 days, and followed by 0 4 ml serum i.p. at 42 days. Half a ml of blood was collected from the tail vein 6 days after the final immunization, to confirm the presence of antibody, and the mice bled out 4 days after the test bleed. Two groups of 6 hairy littermates received normal nude mouse serum witlh the same immunization regime (Groups
Antibodies directed against normal human lymphocytes wTere raised in 6 CBA mice by 3 injections of 1 5x 107 PBL at 0, 7 and 21 days. This antiserum was used as a positive control (MHL Fig. 1 ; T24 gave essentially the same binding ratios.
Screening of one of the more specific antisera (DNM), and one of the remainder .Sa , (ANM), against a panel of 14 different cell lines and PBL is shown in Fig. 3 Absorption of antiserum (DNM) with 0 03-4 ,tg CEA reduced antibody binding pancreatic maximally by 3000 after 15 min at room temperature, at concentrations of CEA mmunized greater than 0 8 Hg. produced As can be seen in Fig. 4 , the amount of for pan-antiserum binding to GER, TCC, J82 and ratio > 2) Absorption of antisera with normal pancreas and a mixed tumour-cell pool Localization of the antisera in frozen tissue sections Positive immunofluorescent staining was seen in sections from all primary pancreatic tumours and tumour xenografts with dilutions of CEA-absorbed antiserum up to 1:100. Areas of strong staining were located around the malignant ductular epithelial cells, and appeared to reflect the degree of morphological differentiation of the tumour; a highly anaplastic poorly differentiated cell population (TUR) showing very little staining, whereas a well differentiated tumour (WB) was strongly positive. Staining of normal and foetal pancreas was found in ductular-cell areas. All sections were negative with hairy anti-normal nude mouse serum and gave a general positive fluorescence with MHL. 
DISCUSSION
Cross-immunization of immunocompetent hairy litter-mates with serum from pancreatic tumour-bearing immunodeficient nude mice has led to the production of antibodies directed against the components released from viable human tumour cells during growth. Nude mice have a normal /-lymphocyte complement (Sprent & Miller, 1972) A mixed response to the polyspecific antiserum was shown by all the cell lines tested, suggesting that antibodies were also raised against common tumour-cell markers (CEA, epithelial-cell markers) and normal cell-surface components that had been shed from the pancreatic tumour cells. Release of these and other surface components may be a normal function of the cell, or may arise from cellular degradation. We had previously reported that pancreatic tumour cells express LHLA and /2 on their cell surface (Pahlman et al., 1979) and this probably explains the high level of antibody binding to a fibroblast cell line (GF) derived from the same patient from whom the tumour cell originated. Very little CEA was detected on the pancreatic tumour cell surface but it was present in the serum of tumourbearing animals which agreed with other studies (Kim et al., 1976) . However, the antibody against CEA could be removed from t,he sera of immunocompetent mice by adsorption with pure CEA without any loss of specificity against pancreatic tumour cells. Binding to a CEA-producing colonic carcinoma cell line (Von Kleist et al., 1975) remained consistently high after CEA adsorption, suggesting that these two gastrointestinally-derived cell lines shared a number of cell-surface components. AFP was not detected in the sera of tumour-bearing animals, and adsorption with pure antigen did not affect the antibody response. Immunofluorescent staining of tissue sections showed that the predominantly antibody response was localized around the membrane of ductular epithelial cells in tumour tissue as well as foetal and normal pancreas. However, the antibodies did not appear to be primarily directed against epithelial cells, since the 2 epithelial tumour-cell lines (SCaBer and MDA) showed only 18% and 19% respectively of the binding level found for pancreatic-cancer cells. Similarly the low level of binding to murine polyoma-virustransformed cells confirmed that the antibodies specifically identified human tumour components.
Absorption of the antisera with a mixed tumour-cell pool and normal pancreas homogenate did not completely abolish the antibody response against pancreatic tumour cells, suggesting the presence of a pancreatic tumour-specific antigen. Although some of the antibody response is likely to be directed against pancreatic antigens that have already been isolated (Schultz & Yunis, 1979 Gelder et al., 1978 it is possible that antibodies may be raised against cell-surface components not normally present in sufficient quantities to be immunogenic. Thus, identification of minor, but possibly important, tumour components might be achieved using this technique, since they will be continually released into the serum during tumour growth. Another of the advantages of this cross-immunization technique is that it offers a novel way of subsequently producing monoclonal antibodies directed against specific antigens released from the tumour cell. Spleens from immunized hairy litter-mates are currently being hybridized with myeloma cells and, since the method permits the exploitation of qualitative and quantitative differences in the recognition of human tumour components by individual immunocompetent mice, it is hoped that the resulting monoclonal antibodies will identify a variety of tumour cell-surface components.
